The inflammatory cytokine profile of myelodysplastic syndromes

Shi, Xin; Zheng, Yanhua; Xu, Lijun; Cao, Chun; Dong, Baowei; Chen, Xiequn

doi:10.1097/md.0000000000015844

Cited by 34 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cytokine elevations cause hypoproliferative bone marrow. A meta-analysis showed that the levels of TNF-α, IL-6, and IL-8 were significantly higher in MDS patients than in controls 31 . TNF-α is released by cytotoxic T cells and induces cell apoptosis in MDS bone marrow 20 .…”

Section: Discussionmentioning

confidence: 99%

Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis

Chang

Lin

et al. 2020

Sci Rep

View full text Add to dashboard Cite

In end-stage renal disease (ESRD) patients receiving dialysis, anemia is common and related to a higher mortality rate. Erythropoietin (EPO) resistance and iron refractory anemia require red blood cell transfusions. Myelodysplastic syndrome (MDS) is a disease with hematopoietic dysplasia. There are limited reports regarding ESRD patients with MDS. We aim to assess whether, for ESRD patients, undergoing dialysis is a predictive factor of MDS by analyzing data from the Taiwan National Health Insurance Research Database. We enrolled 74,712 patients with chronic renal failure (ESRD) who underwent dialysis and matched 74,712 control patients. In our study, we noticed that compared with the non-ESRD controls, in ESRD patients, undergoing dialysis (subdistribution hazard ratio [sHR] = 1.60, 1.16–2.19) and age (sHR = 1.03, 1.02–1.04) had positive predictive value for MDS occurrence. Moreover, more units of red blood cell transfusion (higher than 4 units per month) was also associated with a higher incidence of MDS. The MDS cumulative incidence increased with the duration of dialysis in ESRD patients. These effects may be related to exposure to certain cytokines, including interleukin-1, tumor necrosis factor-α, and tumor growth factor-β. In conclusion, we report the novel finding that ESRD patients undergoing dialysis have an increased risk of MDS.

show abstract

Section: Discussionmentioning

confidence: 99%

Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis

Chang

Lin

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This phenomenon could increase the chronic inflammation process in patients’ bone marrow and subsequently induce DNA instability and promote the emergence of clonal expansion. Among high‐risk patients there is an increase in clonality of the tumor cells, which escape immune surveillance because of the reduction of the immunosuppressive environmental status 36 …”

Section: Discussionmentioning

confidence: 99%

Mannuronic Acid in Low‐Risk and Intermediate‐1‐Risk Myelodysplastic Syndromes

Ghaderi

Nodehi

Bakhtiari

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The discovery of hematologic improvement and bone marrow modification by the drug β‐D mannuronic acid (M2000) during treatment of rheumatoid arthritis in phase 1/2/3 clinical trials prompted us to design a new trial to target hematologic deficits in myelodysplastic syndromes (MDS). In this open‐label, randomized phase 2 clinical trial, the potential effect and tolerability of drug M2000 was assessed in patients with low‐ and intermediate‐1‐risk MDS. The primary efficacy end point was hematologic improvement after 12 weeks of β‐D‐mannuronic acid therapy. Among 34 enrolled patients, half received their conventional therapy plus β‐D‐mannuronic acid, and the other half received only conventional drugs. In the conventional + β‐D mannuronic acid treatment group, hematologic improvement and development of transfusion independence and/or reduction in transfusion requirements were seen in 12 patients (92.3%) and 1 patient (7.7%), respectively. Moreover, 5 patients (38.5%), 2 patients (15.4%), and 1 patient (7.7%) in the β‐D‐mannuronic acid‐treated group showed hematologic improvement of the major parameters of erythroid, neutrophil, and platelet responses, respectively, based on the International Working Group criteria), whereas in the conventional treatment group as control, no hematologic improvements including erythroid, neutrophil, and platelet response was seen. In this trial, the addition of β‐D mannuronic acid to conventional treatment showed promising results in MDS patients with low and intermediate‐1 risk with effects on hematologic improvements without significant adverse effect.

show abstract

“…The effect of infl ammation and immunological microenvironment on the pathogenesis of MDS was observed in recently published data (12). In studies involving low-risk MDS patients, T lymphocyte-mediated inhibition of hematopoiesis was observed.…”

Section: Introductionmentioning

confidence: 90%

Does the platelet‑to‑lymphocyte ratio have a prognostic effect in patients with myelodysplastic syndrome?

Yıkılmaz¹,

Akıncı²,

Bakanay³

et al. 2020

BLL

View full text Add to dashboard Cite

INTRODUCTION: Myelodysplastic syndromes (MDS) include various hematologic abnormalities characterized by chronic cytopenia due to disruption in cellular differentiation. This study aims to evaluate the prognostic value of PLR in patients with MDS. MATERIAL AND METHODS: Clinical-laboratory fi ndings and the results of bone marrow biopsies of MDS patients before treatment were recorded. p value of < 0.05 was considered statistically signifi cant. SPSS version 20.0 was used for statistical analysis. RESULTS: The study included 62 patients with median follow-up time of 62.8 ± 4.5 months and median age of 68.5 years. In 13 patients, acute leukemia was transformed. In these subjects, a PLR cutoff level of 46 was established for mortality (p = 0.015). We found a signifi cant relationship between PLR and multilineage series with the presence of dysplasia (p = 0.017). The survival analysis showed a decreased survival in cases with dysplasia in two and/or more series, transformation into acute leukemia, and thrombocytopenia. CONCLUSION: Our study demonstrated that there was a relationship between PLR and MDS with multilineage dysplasia (mld-MDS). PLR is investigated as an infl ammatory fi nding in various hematologic malignancies. Further studies investigating the value of PLR in MDS are needed to determine whether PLR may be a marker of bone marrow dysplasia grading (Tab. 2, Fig. 4, Ref. 32).

show abstract

The inflammatory cytokine profile of myelodysplastic syndromes

Cited by 34 publications

References 30 publications

Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis

Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis

Mannuronic Acid in Low‐Risk and Intermediate‐1‐Risk Myelodysplastic Syndromes

Does the platelet‑to‑lymphocyte ratio have a prognostic effect in patients with myelodysplastic syndrome?

Contact Info

Product

Resources

About